Sage Therapeutics (SAGE) Competitors $7.43 +0.06 (+0.81%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$7.42 -0.01 (-0.20%) As of 04/17/2025 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SAGE vs. HRMY, BEAM, GLPG, CNTA, AGIO, KNSA, ANIP, APGE, JANX, and KYMRShould you be buying Sage Therapeutics stock or one of its competitors? The main competitors of Sage Therapeutics include Harmony Biosciences (HRMY), Beam Therapeutics (BEAM), Galapagos (GLPG), Centessa Pharmaceuticals (CNTA), Agios Pharmaceuticals (AGIO), Kiniksa Pharmaceuticals (KNSA), ANI Pharmaceuticals (ANIP), Apogee Therapeutics (APGE), Janux Therapeutics (JANX), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry. Sage Therapeutics vs. Harmony Biosciences Beam Therapeutics Galapagos Centessa Pharmaceuticals Agios Pharmaceuticals Kiniksa Pharmaceuticals ANI Pharmaceuticals Apogee Therapeutics Janux Therapeutics Kymera Therapeutics Sage Therapeutics (NASDAQ:SAGE) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, community ranking, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings. Does the MarketBeat Community favor SAGE or HRMY? Sage Therapeutics received 567 more outperform votes than Harmony Biosciences when rated by MarketBeat users. However, 70.97% of users gave Harmony Biosciences an outperform vote while only 65.12% of users gave Sage Therapeutics an outperform vote. CompanyUnderperformOutperformSage TherapeuticsOutperform Votes63365.12% Underperform Votes33934.88% Harmony BiosciencesOutperform Votes6670.97% Underperform Votes2729.03% Do institutionals & insiders have more ownership in SAGE or HRMY? 99.2% of Sage Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 5.5% of Sage Therapeutics shares are owned by company insiders. Comparatively, 30.8% of Harmony Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has better earnings and valuation, SAGE or HRMY? Harmony Biosciences has higher revenue and earnings than Sage Therapeutics. Sage Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSage Therapeutics$41.24M11.08-$400.67M-$6.59-1.13Harmony Biosciences$714.73M2.28$128.85M$2.5111.34 Do analysts recommend SAGE or HRMY? Sage Therapeutics currently has a consensus price target of $8.81, indicating a potential upside of 18.61%. Harmony Biosciences has a consensus price target of $53.33, indicating a potential upside of 87.40%. Given Harmony Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Harmony Biosciences is more favorable than Sage Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sage Therapeutics 2 Sell rating(s) 15 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00Harmony Biosciences 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer SAGE or HRMY? In the previous week, Sage Therapeutics and Sage Therapeutics both had 6 articles in the media. Harmony Biosciences' average media sentiment score of 1.48 beat Sage Therapeutics' score of 0.81 indicating that Harmony Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sage Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harmony Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, SAGE or HRMY? Sage Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Is SAGE or HRMY more profitable? Harmony Biosciences has a net margin of 17.98% compared to Sage Therapeutics' net margin of -971.50%. Harmony Biosciences' return on equity of 23.16% beat Sage Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sage Therapeutics-971.50% -68.18% -60.84% Harmony Biosciences 17.98%23.16%14.24% SummaryHarmony Biosciences beats Sage Therapeutics on 14 of the 17 factors compared between the two stocks. Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SAGE vs. The Competition Export to ExcelMetricSage TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$453.12M$6.44B$5.29B$7.35BDividend YieldN/A3.23%5.12%4.31%P/E Ratio-1.136.8821.7117.77Price / Sales11.08231.36379.3997.65Price / CashN/A65.6738.2234.64Price / Book0.985.916.443.98Net Income-$400.67M$142.72M$3.21B$247.44M7 Day Performance3.77%4.33%2.81%1.82%1 Month Performance-5.47%-12.80%-8.67%-6.98%1 Year Performance-43.00%-9.71%11.32%1.49% Sage Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SAGESage Therapeutics3.8739 of 5 stars$7.43+0.8%$8.81+18.6%-40.9%$453.12M$41.24M-1.13690Analyst RevisionHRMYHarmony Biosciences4.5507 of 5 stars$28.40-2.9%$53.33+87.8%-2.5%$1.63B$714.73M13.46200Short Interest ↓Positive NewsBEAMBeam Therapeutics2.9794 of 5 stars$15.30+0.2%$49.45+223.2%-30.1%$1.53B$63.52M-8.69510Short Interest ↑High Trading VolumeGLPGGalapagos0.6795 of 5 stars$23.04-3.0%$25.33+10.0%-15.6%$1.52B$275.65M0.001,123Upcoming EarningsHigh Trading VolumeCNTACentessa Pharmaceuticals2.9228 of 5 stars$11.28-3.4%$27.71+145.7%+14.1%$1.50B$6.85M-7.37200Positive NewsHigh Trading VolumeAGIOAgios Pharmaceuticals3.9476 of 5 stars$25.90+0.5%$56.57+118.4%-4.7%$1.48B$36.50M2.28390KNSAKiniksa Pharmaceuticals2.5973 of 5 stars$20.28-0.4%$37.17+83.3%+19.2%$1.47B$423.24M-144.85220Upcoming EarningsAnalyst ForecastInsider TradePositive NewsGap UpHigh Trading VolumeANIPANI Pharmaceuticals3.623 of 5 stars$66.99-0.8%$79.75+19.0%+5.7%$1.46B$614.38M-121.80600Analyst UpgradeHigh Trading VolumeAPGEApogee Therapeutics2.1058 of 5 stars$32.30-0.1%$92.17+185.3%-35.7%$1.45BN/A-13.3591News CoverageJANXJanux Therapeutics2.7304 of 5 stars$24.38-5.4%$92.44+279.2%-38.1%$1.44B$10.59M-20.8430Gap DownHigh Trading VolumeKYMRKymera Therapeutics1.4813 of 5 stars$22.01-0.3%$56.36+156.1%-23.1%$1.43B$47.07M-9.41170Positive NewsGap UpHigh Trading Volume Related Companies and Tools Related Companies Harmony Biosciences Competitors Beam Therapeutics Competitors Galapagos Competitors Centessa Pharmaceuticals Competitors Agios Pharmaceuticals Competitors Kiniksa Pharmaceuticals Competitors ANI Pharmaceuticals Competitors Apogee Therapeutics Competitors Janux Therapeutics Competitors Kymera Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SAGE) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersThe Last Time Stocks Looked Like This, They Didn’t Move For 16 YearsThere is nothing the Federal Reserve can do to stop what's coming next for U.S. stocks. As you've seen your...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SAGE Stock Free SAGE Stock Alerts